Neumora Therapeutics, Inc. (NMRA)
0.3339
-0.01
(-3.78%)
USD |
NASDAQ |
Nov 20, 16:00
0.3387
0.00 (0.00%)
After-Hours: 20:00
Neumora Therapeutics Research and Development Expense (TTM) : 135.16M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 135.16M |
| June 30, 2026 | 153.07M |
| March 31, 2026 | 162.51M |
| December 31, 2025 | 176.06M |
| September 30, 2025 | 177.31M |
| June 30, 2025 | 197.42M |
| March 31, 2025 | 207.32M |
| December 31, 2024 | 200.93M |
| September 30, 2024 | 193.88M |
| Date | Value |
|---|---|
| June 30, 2024 | 174.85M |
| March 31, 2024 | 158.99M |
| December 31, 2023 | 142.72M |
| September 30, 2023 | 127.38M |
| June 30, 2023 | 108.33M |
| March 31, 2023 | 99.08M |
| December 31, 2022 | 91.75M |
| September 30, 2022 | 79.73M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| EyePoint, Inc. | 296.65M |
| Context Therapeutics, Inc. | 37.10M |
| LENZ Therapeutics, Inc. | 0.00 |
| ANI Pharmaceuticals, Inc. | 50.60M |
| Corcept Therapeutics, Inc. | 241.72M |